Hot Features
프리미엄
Zevra Therapeutics Inc (ZVRA)
NASDAQ
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. 더 보기
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™, Zevra’s comprehensive patient support program...
FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0501 | 0.629396984925 | 7.96 | 8.34 | 7.9 | 294838 | 8.1341404 | CS |
| 4 | -0.5299 | -6.20491803279 | 8.54 | 8.95 | 7.61 | 392773 | 8.23001605 | CS |
| 12 | -0.1599 | -1.95716034272 | 8.17 | 9.76 | 7.61 | 535464 | 8.68742426 | CS |
| 26 | 1.8401 | 29.8233387358 | 6.17 | 9.76 | 5.45 | 826023 | 7.82244594 | CS |
| 52 | 2.0401 | 34.1725293132 | 5.97 | 9.76 | 4.2 | 546428 | 7.25447315 | CS |
| 156 | 2.3601 | 41.7716814159 | 5.65 | 9.76 | 3.89 | 398198 | 6.6848504 | CS |
| 260 | 2.3601 | 41.7716814159 | 5.65 | 9.76 | 3.89 | 398198 | 6.6848504 | CS |
236T568
57 초 전
Lime Time
59 초 전
fuagf
1 분 전
ChannelTrader
1 분 전
capgain
2 분 전
Zorax
2 분 전
trunkmonk
3 분 전
stevo321
3 분 전
lighter than AIR
3 분 전
oystersnbeer
4 분 전
StayHumble
4 분 전
LCJR
4 분 전
redspinelpinktopaz
4 분 전
Ely
5 분 전
Wingsjr
5 분 전
delerious1
6 분 전
redspinelpinktopaz
7 분 전
StayHumble
7 분 전
gitreal
7 분 전
wxdog
8 분 전
peanutz
8 분 전
DjScottyT
9 분 전
RMS555
10 분 전
StayHumble
10 분 전
